• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Bris­tol-My­ers part­ners with En­terome on a gut-lev­el ap­proach to im­muno-on­col­o­gy; Mor­phoSys adds $126M

9 years ago
News Briefing

Sput­nik 2.0? Chi­nese re­search team first to try CRISPR-Cas9 gene-edit­ing tech on a hu­man

9 years ago
China

Med­i­cines Co, Al­ny­lam gen­er­ate pos­i­tive buzz with ev­i­dence of a durable, 6-month LDL re­sponse to PC­SK9 ri­val

9 years ago
R&D

Low-pro­file Be­yond­Spring files for $100M IPO to back can­cer work; Ery­tech ham­mered af­ter it pulls mar­ket­ing ...

9 years ago
News Briefing

The Park­er In­sti­tute aims to speed up can­cer R&D, carv­ing out du­pli­cate IRBs at top cen­ters

9 years ago
R&D

Roche har­ness­es a net­work of aca­d­e­m­ic I/O re­searchers in $100M glob­al col­lab­o­ra­tive

9 years ago
R&D

Ab­b­Vie, Enan­ta hep C com­bo looks stel­lar in CKD study as ri­vals hus­tle along the lat­est cures

9 years ago
R&D
Pharma

Strug­gling gene ther­a­py pi­o­neer uniQure brings out the ax, chop­ping pro­grams and staffers in over­haul

9 years ago
R&D

Promis­ing or in­con­clu­sive? Gilead fields PhII GS-4997 da­ta, trig­ger­ing more push­back on NASH claims

9 years ago
R&D

Puma shares ripped af­ter grow­ing grade 3 di­ar­rhea threat is high­light­ed in an ab­stract

9 years ago
R&D

Did Mer­ck KGaA’s ag­ing at­aci­cept just fail a PhI­Ib lu­pus tri­al? Well, yes, but…

9 years ago
R&D

No­var­tis’ ‘break­through’ AML drug gets ac­cel­er­at­ed FDA re­view; Oc­u­lar surges on pos­i­tive PhI­II eye study

9 years ago
News Briefing

Step 3: Sanofi com­mits up to $100M to opt-in on Al­ny­lam’s PhI­II RNAi he­mo­phil­ia tri­al

9 years ago
R&D

Dy­navax shares crater af­ter the FDA re­jects Hep­lisav-B, again, and CEO sig­nals for help

9 years ago
R&D

Un­der a short as­sault, Cor­bus coun­ter­at­tacks with pos­i­tive PhII da­ta for sys­temic scle­ro­sis drug

9 years ago
R&D

J&J, GSK stum­ble com­ing out of the gate with mixed PhI­II rheuma­toid arthri­tis da­ta for sirukum­ab

9 years ago
R&D

Biotech in­sid­er Rich Bag­ger is out, Gin­grich is up in lat­est reshuf­fle of Trump’s in­ner cir­cle

9 years ago
People
Pharma

Bris­tol-My­ers part­ners with Johns Hop­kins on Op­di­vo pact; A Valeant by any oth­er name…

9 years ago
News Briefing

The longterm im­pli­ca­tions of the Trump Bump; Let’s try again on drug pric­ing

9 years ago
Bioregnum
Opinion

Po­laris cash­es in its chips as Langer-backed Ar­sia is auc­tioned off to Ea­gle for up to $78M

9 years ago
R&D

Ul­tragenyx nix­es plan to seek quick OK for rare dis­ease drug in Eu­rope

9 years ago
R&D

PTC shares rock­et up as Eu­ro­pean reg­u­la­tors of­fer a thumbs-up on Duchenne drug mar­ket­ing

9 years ago
R&D

Don­ald Trump sends a vague­ly word­ed love let­ter to bio­phar­ma as stock ral­ly con­tin­ues

9 years ago
People
Pharma

Klein­er Perkins-backed El­celyx says its re­for­mu­lat­ed met­formin worked in a PhI­Ib di­a­betes study

9 years ago
R&D
First page Previous page 1145114611471148114911501151 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.